文献

J-GLOBAL ID：202202225581906922   整理番号：22A0951735

抗レトロウイルス療法におけるHIV患者の持続性低レベルウイルス血症の転帰: 前向きコホート研究【JST・京大機械翻訳】

Outcomes of persistent low-level viremia among HIV patients on antiretroviral therapy: A prospective cohort study

著者 (44件)： Ding Haibo (NHC Key Laboratory of AIDS Immunology, China Medical University, National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China) ,  Ding Haibo (Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, China) ,  Ding Haibo (Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China) ,  Ding Haibo (Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China) ,  Xu Junjie (NHC Key Laboratory of AIDS Immunology, China Medical University, National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China) ,  Xu Junjie (Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, China) ,  Xu Junjie (Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China) ,  Xu Junjie (Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China) ,  Liu Jing (NHC Key Laboratory of AIDS Immunology, China Medical University, National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China) ,  Liu Jing (Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, China) ,  Liu Jing (Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China) ,  Liu Jing (Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China) ,  Wang Qi (NHC Key Laboratory of AIDS Immunology, China Medical University, National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China) ,  Wang Qi (Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, China) ,  Wang Qi (Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China) ,  Wang Qi (Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China) ,  Kang Jing (NHC Key Laboratory of AIDS Immunology, China Medical University, National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China) ,  Kang Jing (Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, China) ,  Kang Jing (Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China) ,  Kang Jing (Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China) ,  Li Xiaolin (NHC Key Laboratory of AIDS Immunology, China Medical University, National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China) ,  Li Xiaolin (Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, China) ,  Li Xiaolin (Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China) ,  Li Xiaolin (Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China) ,  Zhang Zining (NHC Key Laboratory of AIDS Immunology, China Medical University, National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China) ,  Zhang Zining (Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, China) ,  Zhang Zining (Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China) ,  Zhang Zining (Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China) ,  Han Xiaoxu (NHC Key Laboratory of AIDS Immunology, China Medical University, National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China) ,  Han Xiaoxu (Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, China) ,  Han Xiaoxu (Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China) ,  Han Xiaoxu (Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China) ,  Jiang Yongjun (NHC Key Laboratory of AIDS Immunology, China Medical University, National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China) ,  Jiang Yongjun (Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, China) ,  Jiang Yongjun (Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China) ,  Jiang Yongjun (Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China) ,  Geng Wenqing (NHC Key Laboratory of AIDS Immunology, China Medical University, National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China) ,  Geng Wenqing (Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, China) ,  Geng Wenqing (Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China) ,  Geng Wenqing (Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China) ,  Shang Hong (NHC Key Laboratory of AIDS Immunology, China Medical University, National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China) ,  Shang Hong (Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, China) ,  Shang Hong (Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China) ,  Shang Hong (Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China)
資料名： Hiv Medicine  (Hiv Medicine)
巻： 23 Suppl S1  ページ： 64-71  発行年： 2022年 
JST資料番号： W2599A  ISSN： 1464-2662  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： アメリカ合衆国 (USA)  言語： 英語 (EN)

抄録/ポイント： 序論:低レベルウイルス血症(LLV)とウイルス学的障害(VF),死亡,および非AIDSイベント(NAE)の間の関係を検討した。方法:抗レトロウイルス療法(ART)でHIV(PLHIV)を生活する人々の前向きコホート研究を,中国, Shenyang陽のHIVクリニックで2011~2018年に実施した。VFの発生率とLLVによる死亡率とNAEを評価した。Cox比例ハザード回帰を行い,VF,死亡率およびNAEの危険因子を検討した。結果:合計1288人の患者で,追跡調査の3915人年(追跡期間中央値,2.5年[四分位範囲:2~4年])が登録された。31人の患者(2.4%)はVFを経験し,5人(0.4%)は死亡し,38人(3.0%)はNAEsを経験した。VFのリスクは,ウイルス負荷(VL)が200~499コピー/mL(調整ハザード比[aHR]:14.92,95%信頼区間[CI]:5.92~37.60)または500~999コピー/mL(aHR:13.68,95%CI:3.61~51.87)の患者の間で有意に増加したが,VLが50~199コピー/mL(aHR:3.10,95%CI:0.86~11.09)の患者ではそうではなかった。NAEのリスクは,LLV(aHR:7.33,95%CI:3.73~14.42)の患者で有意に増加した。LLVと比較して,VLは50-199コピー/mL(aHR:4.11,95%CI:1.73-9.74),200-499コピー/mL(aHR:18.31,95%CI:6.66-50.33),および500-999コピー/mL(aHR:21.34,95%CI:5.69-80.01)はNAEのより高いリスクを示した。結論:低レベルウイルス血症はVFとNAEと関連していた。LLV,特にVL≧200コピー/mLの患者は,より頻繁なVL試験およびNAEスクリーニングを必要とする。Copyright 2022 Wiley Publishing Japan K.K. All rights reserved. Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： 死亡率 ,  中華人民共和国 ,  スクリーニング ,  後天性免疫不全症候群 ,  *ウイルス血症 ,  *HIV【ウイルス】 ,  危険因子 ,  追跡調査 ,  *前向きコホート研究
準シソーラス用語： ウイルス負荷 ,  *高活性抗レトロウイルス療法 ,  ウイルス学 ,  ハザード比 ,  比例ハザード , 【Automatic Indexing@JST】

著者キーワード (5件)： 中国 ,  低レベルウイルス血症 ,  非AIDSイベント ,  HIVと生活する人々 ,  ウイルス学的失敗

分類 (3件)： 感染症・寄生虫症一般  (GD01010H) ,  循環系の疾患  (GJ03000C) ,  感染症・寄生虫症の治療  (GD01030D)

タイトルに関連する用語 (7件)： 抗レトロウイルス療法 ,  HIV ,  患者 ,  持続性 ,  ウイルス血症 ,  転帰 ,  前向きコホート研究